TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4050737

Group type: EXPERIMENTAL
Intervention: Continuous-course radiotherapy (6,000 cGy in 30 fractions of 200 cGy each, over 6 weeks)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Split-course radiotherapy (2,750 cGy in 10 fractions of 275 cGy each, over 2 weeks; a rest period of 3 weeks; 2,750 cGy in 2 weeks)
Number of subjects: 148
Study: 31678689

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) based on multivariate analysis with Cox proportional hazards regression.
Number of subjects: 19796

Group type: COMPARATOR
Intervention: Training cohort (n = 13,860) and validation cohort (n = 5,936) used for analysis.
Number of subjects: 19796
Study: 28962869

Group type: EXPERIMENTAL
Intervention: High provider anxiety
Number of subjects: 148

Group type: COMPARATOR
Intervention: Low provider anxiety
Number of subjects: 148
Study: 27182015

Group type: EXPERIMENTAL
Intervention: Drinking prevention program for preschool children (6 weeks duration)
Number of subjects: 123
Study: 25148184

Group type: EXPERIMENTAL
Intervention: MR enterography measurement
Number of subjects: 31
Study: 22945714

Group type: EXPERIMENTAL
Intervention: Ca(OH) 2 placed in the dried pulp chamber
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ca(OH) 2 placed in dried root canals
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (canals remained wet without medication)
Number of subjects: 99
Study: 20864904

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19012119

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 47
Study: 16816529

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study: 14531869

Group type: EXPERIMENTAL
Intervention: Lyral in ethanol (6% to 6 p.p.m)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle control of ethanol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (7 subjects)
Number of subjects: 25
Study: 10448445

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7479231

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 15
Study: 2129319

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg PM
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg bid
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg AM
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Pravastatin (all regimens)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 364999

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDX)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Desmethylchlordiazepoxide (DMCDX)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Demoxepam (DMX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30982356

Group type: EXPERIMENTAL
Intervention: Edaravone treatment in Study MCI186-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in Study MCI186-16
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in Study MCI186-19
Number of subjects: 0
Study: 29871204

Group type: EXPERIMENTAL
Intervention: Saline nasal irrigation at 40 degrees
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline nasal irrigation at 25 degrees (control)
Number of subjects: 120
Study: 25521103

Group type: EXPERIMENTAL
Intervention: PP-501-B
Number of subjects: 103

Group type: COMPARATOR
Intervention: Restylane Perlane
Number of subjects: 103
Study: 23344712

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day (fasted) on Days 2-8 and 1,600 mg (with food) on Day 9
Number of subjects: 96

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 96
Study: 20840529

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 20 mg hyperbaric bupivacaine and 0.2 mg morphine
Number of subjects: 162

Group type: COMPARATOR
Intervention: General anaesthesia with propofol, fentanyl and rocuronium
Number of subjects: 162
Study: 18030490

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposures (IHE) for 10 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo control for 10 days
Number of subjects: 8
Study: 16423331

Group type: EXPERIMENTAL
Intervention: 30 mg memantine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12603365

Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 0
Study: 11445103

Group type: EXPERIMENTAL
Intervention: Human IgG 1200 mg/kg daily
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 9727900

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/day for 3 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 29
Study: 8021679

Group type: EXPERIMENTAL
Intervention: Enhanced therapy for arm function
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 97
Study: 2690785

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21529904

Group type: EXPERIMENTAL
Intervention: Maintenance low-dose paclitaxel 40 mg/m²/week for 24 weeks
Number of subjects: 542

Group type: COMPARATOR
Intervention: Observation (no maintenance therapy)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Maintenance low-dose paclitaxel
Number of subjects: 542

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 542
Study: 6985833

Group type: EXPERIMENTAL
Intervention: Depo-Provera
Number of subjects: 114

Group type: COMPARATOR
Intervention: Delalutin
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 114
Study: 31279925

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 68
Study: 29650688

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy (doxorubicin, doxorubicin + ifosfamide, epirubicin, trabectedin, ifosfamide)
Number of subjects: 348

Group type: COMPARATOR
Intervention: First-line chemotherapy (for patients aged <65 years)
Number of subjects: 348
Study: 26868683

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose (LD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose (LD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 100
Study: 24852464

Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream applied every day for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: 4 weekly peels of 5% 5-fluorouracil
Number of subjects: 32
Study: 22573238

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin arm
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Increases in ESA doses (>0 U)
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Larger increases in hemoglobin (>1.0 g/dL/month)
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Increasing DBP
Number of subjects: 1421
Study: 19092242

Group type: EXPERIMENTAL
Intervention: FIO2 of 15% for 10 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FIO2 of 10% for 10 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Room air (RA) for 20 min (control)
Number of subjects: 18
Study: 17467411

Group type: EXPERIMENTAL
Intervention: Placebo expectation condition
Number of subjects: 56

Group type: COMPARATOR
Intervention: Treatment control condition
Number of subjects: 56

Group type: COMPARATOR
Intervention: No‐placebo control condition
Number of subjects: 56
Study: 15178637

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study: 12077469

Group type: EXPERIMENTAL
Intervention: Moisturiser containing urea and sodium chloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Moisturiser containing urea alone
Number of subjects: 23
Study: 10097818

Group type: EXPERIMENTAL
Intervention: Recombinant thrombopoietin therapy; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short peptides with Tpo activity; details on dosage and duration not available.
Number of subjects: 0
Study: 7651063

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2649192

Group type: EXPERIMENTAL
Intervention: Conray 325 (sodium iothalamate)
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Niopam 300 (iopamidol)
Number of subjects: 1699
Study: 333693

Group type: EXPERIMENTAL
Intervention: Lioresal (antispasticity drug)
Number of subjects: 15
Study: 31511041

Group type: EXPERIMENTAL
Intervention: Multimodal cardioprotective strategy (remote ischemic preconditioning, sevoflurane anesthesia, tight blood glucose management, moderate respiratory acidosis, gentle reperfusion protocol)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Total intravenous anesthesia with propofol and liberal intraoperative blood glucose management
Number of subjects: 210
Study: 28512669

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser (NAF) with fractional micro-needling radiofrequency (FMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ablative fractional laser (NAF) alone
Number of subjects: 0
Study: 26431123

Group type: EXPERIMENTAL
Intervention: Physical, cognitive, and mindfulness group-based training (PCMT group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 112
Study: 23992381

Group type: EXPERIMENTAL
Intervention: Gelatin sponge particles
Number of subjects: 60

Group type: COMPARATOR
Intervention: nPVA
Number of subjects: 60
Study: 21334243

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T
Number of subjects: 412

Group type: COMPARATOR
Intervention: DTaP-IPV-Hep B//PRP-T
Number of subjects: 412
Study: 19825891

Group type: EXPERIMENTAL
Intervention: Precision reflexology
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham reflexology
Number of subjects: 73
Study: 16764198

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15039412

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study: 11295008

Group type: EXPERIMENTAL
Intervention: Home injections by the nurse practitioner
Number of subjects: 89

Group type: COMPARATOR
Intervention: Hospital outpatient clinic injections by medical staff
Number of subjects: 89
Study: 9047153

Group type: EXPERIMENTAL
Intervention: sTNFR:Fc therapy (low-dose 0.05 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sTNFR:Fc therapy (high-dose 0.15 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sTNFR:Fc therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients receiving OKT3 therapy
Number of subjects: 0
Study: 8451040

Group type: EXPERIMENTAL
Intervention: Oral medium-dosed metoclopramide (MCL, 3.5 mg/kg b.w./cycle)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3530049

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine, 1.5 mg/kg, administered 2 minutes before laryngoscopy and intubation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and saline)
Number of subjects: 16
Study: 31872408

Group type: EXPERIMENTAL
Intervention: Checklist-based critical appraisal
Number of subjects: 51

Group type: COMPARATOR
Intervention: Free critical appraisal
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 27793737

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin plus an aminoglycoside
Number of subjects: 322

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 322
Study: 27127998

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 800/100 mcg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 800 mcg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vilanterol (VI) 100 mcg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23289013

Group type: EXPERIMENTAL
Intervention: Visfatin RS4730153 AG genotype
Number of subjects: 88

Group type: COMPARATOR
Intervention: Visfatin RS4730153 GG genotype
Number of subjects: 88
Study: 21240023

Group type: EXPERIMENTAL
Intervention: Rifaximin (550 mg, 3 times per day for 10 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (3 times per day for 10 days)
Number of subjects: 75
Study: 18308741

Group type: COMPARATOR
Intervention: Terlipressin 1 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Terlipressin 1 mg followed by dobutamine infusion titrated to reverse the anticipated reduction in Svo2
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sole norepinephrine infusion (control)
Number of subjects: 59
Study: 17080767

Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 12742873

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting-list (WL) control
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: General psychopathologic and depressive symptoms
Number of subjects: 43
Study: 10911766

Group type: EXPERIMENTAL
Intervention: 677CC/1298AA genotype
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 677CC/1298AC genotype
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 677CC/1298CC genotype
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 677CT/1298AC genotype
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 677TT and 1298CC genotypes
Number of subjects: 66
Study: 8656390

Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 60
Study: 1508058

Group type: EXPERIMENTAL
Intervention: Oestriol (E3) 0.5 mg administered intravaginally daily for 2 weeks, then once or twice weekly for 4 weeks as maintenance dose.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maintenance doses of E3 (once or twice weekly) after initial treatment.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual assessment method for vaginal epithelium maturation.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E3 treatment.
Number of subjects: 40
Study: 6579633

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g bd
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g nocte
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 30870778

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (WP) with placebo (PLA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Placebo with whey protein (PLA-WP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo with placebo (PLA-PLA)
Number of subjects: 70
Study: 29227052

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Clinical and radiological follow-up (Group B)
Number of subjects: 58
Study: 24166937

Group type: EXPERIMENTAL
Intervention: Narrative therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 24118972

Group type: EXPERIMENTAL
Intervention: Once daily PTNS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice weekly PTNS
Number of subjects: 30
Study: 21658527

Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching (PFC) delivered in eight, 90-minute sessions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 18572266

Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Number of subjects: 80

Group type: COMPARATOR
Intervention: standard epirubicin
Number of subjects: 80
Study: 16710750

Group type: EXPERIMENTAL
Intervention: Long schedule; estrogen began on the first day of menstruation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard schedule; estrogen began on the day of planned egg retrieval
Number of subjects: 20
Study: 15204160

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream plus PUVA therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vehicle (placebo) plus PUVA therapy
Number of subjects: 120
Study: 11264634

Group type: EXPERIMENTAL
Intervention: Clotrimazole (10 mg troche, three times daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nystatin (5 mL oral suspension, four times daily)
Number of subjects: 35
Study: 8319838

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, 3 times at 8-hour intervals on the day of ERCP +/− EST)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Nifedipine and Placebo
Number of subjects: 166
Study: 3729097

Group type: EXPERIMENTAL
Intervention: Guidewire catheterization (GW)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nonguidewire catheterization (NGW)
Number of subjects: 210
Study: 29920778

Group type: EXPERIMENTAL
Intervention: Implant-supported removable partial dental prostheses (ISRPDPs) on the reconstructed side (Side R)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control side (Side N)
Number of subjects: 10
Study: 26673560

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 13264

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 13264

Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥ 10 medications)
Number of subjects: 13264
Study: 23543358

Group type: EXPERIMENTAL
Intervention: Educator-implemented intervention (reading storybooks and conducting stimulation activities)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Educator-implemented intervention (with reliable implementation)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control condition (no specific intervention)
Number of subjects: 222
Study: 22084412

Group type: EXPERIMENTAL
Intervention: 20 mg enoxaparin
Number of subjects: 11794

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 11794

Group type: EXPERIMENTAL
Intervention: enoxaparin (20 mg or 40 mg)
Number of subjects: 11794
Study: 20845216

Group type: EXPERIMENTAL
Intervention: 20-min ice-bag application
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 60-min gel-pack application at 10 degrees C
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 60-min gel-pack application at 17 degrees C
Number of subjects: 7

Group type: COMPARATOR
Intervention: non-cooling treatment
Number of subjects: 7
Study: 18664560

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day for 2 years
Number of subjects: 290

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 290
Study: 15856335

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training (PMRT) and guided imagery (GI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 12719503

Group type: EXPERIMENTAL
Intervention: Nurse-administered Structured Clinical Interview for DSM-IV-Clinician Version (SCID)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control condition (no SCID)
Number of subjects: 296
Study: 10554388

Group type: EXPERIMENTAL
Intervention: Waking-alert procedure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active-alert procedure
Number of subjects: 80
Study: 7490838

Group type: EXPERIMENTAL
Intervention: 8 months of reversible androgen ablation therapy
Number of subjects: 50
Study: 1586932

Group type: EXPERIMENTAL
Intervention: Enalapril (3 months therapy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sclerotherapy and placebo (control group)
Number of subjects: 12
Study: 3156909

Group type: EXPERIMENTAL
Intervention: R011-1163
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 25
Study: 31354243

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 104
Study: 28787243

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT, n=31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low-Intensity Training (LIT, n=31)
Number of subjects: 62
Study: 27388281

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 28
Study: 25496504

Group type: EXPERIMENTAL
Intervention: Inhaled PGE1 (IPGE1) at low dose (150 ng/kg/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Inhaled PGE1 (IPGE1) at high dose (300 ng/kg/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Aerosolized saline (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Overall recruitment
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Primary outcome of enrollment
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 7
Study: 22800625

Group type: EXPERIMENTAL
Intervention: Delayed clamping (1 min after delivery)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Early clamping (< 15 s after delivery)
Number of subjects: 158
Study: 20410252

Group type: EXPERIMENTAL
Intervention: Additional psychological treatment (written information on medical and psychological consequences of an ICD plus 6 months of individual phone counseling)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual medical aftercare
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Additional psychological treatment
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: All patients (ICD patients)
Number of subjects: 119